Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All molnupiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Symp. case, MITT 24% Improvement Relative Risk Molnupiravir  MOVe-AHEAD  Prophylaxis  DB RCT Is prophylaxis with molnupiravir beneficial for COVID-19? Double-blind RCT 1,527 patients in multiple countries Fewer symptomatic cases with molnupiravir (not stat. sig., p=0.057) c19early.org Alpizar et al., J. Infection, September 2023 Favors molnupiravir Favors control

Molnupiravir for Intra-Household Prevention of COVID-19: the MOVe-AHEAD Randomized, Placebo-Controlled Trial

Alpizar et al., Journal of Infection, doi:10.1016/j.jinf.2023.08.016, MOVe-AHEAD, NCT04939428
Sep 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
PEP RCT 1,527 patients showing lower COVID-19 cases with molnupiravir, without statistical significance.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer Chamod, Hadj Hassine, Huntsman, Marikawa, Swanstrom, Waters, Zhou, Zibat. Multiple analyses have identified variants potentially created by molnupiravir Fountain-Jones, Kosakovsky Pond, Sanderson, twitter.com.
risk of symptomatic case, 24.2% lower, RR 0.76, p = 0.06, treatment 78 of 763 (10.2%), control 103 of 764 (13.5%), NNT 31, MITT.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alpizar et al., 8 Sep 2023, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 18 authors, trial NCT04939428 (history) (MOVe-AHEAD).
This PaperMolnupiravirAll
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit